HRP980532B1 - Novel crystalline torasemide modification - Google Patents
Novel crystalline torasemide modificationInfo
- Publication number
- HRP980532B1 HRP980532B1 HR980532A HRP980532A HRP980532B1 HR P980532 B1 HRP980532 B1 HR P980532B1 HR 980532 A HR980532 A HR 980532A HR P980532 A HRP980532 A HR P980532A HR P980532 B1 HRP980532 B1 HR P980532B1
- Authority
- HR
- Croatia
- Prior art keywords
- torasemide
- new
- preparation
- modification
- form iii
- Prior art date
Links
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 title abstract 5
- 229960005461 torasemide Drugs 0.000 title abstract 5
- 230000004048 modification Effects 0.000 title abstract 3
- 238000012986 modification Methods 0.000 title abstract 3
- 239000013078 crystal Substances 0.000 abstract 2
- 230000020477 pH reduction Effects 0.000 abstract 2
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 230000003266 anti-allergic effect Effects 0.000 abstract 1
- 230000001088 anti-asthma Effects 0.000 abstract 1
- 230000001773 anti-convulsant effect Effects 0.000 abstract 1
- 239000000924 antiasthmatic agent Substances 0.000 abstract 1
- 239000001961 anticonvulsive agent Substances 0.000 abstract 1
- 229960003965 antiepileptics Drugs 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 230000001882 diuretic effect Effects 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000021822 hypotensive Diseases 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 235000005985 organic acids Nutrition 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Liquid Crystal Substances (AREA)
- Liquid Crystal (AREA)
Priority Applications (37)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HR980532A HRP980532B1 (en) | 1998-10-02 | 1998-10-02 | Novel crystalline torasemide modification |
ES99949272T ES2237158T3 (es) | 1998-10-02 | 1999-10-01 | Nueva modificcion cristalina n de torasemida. |
CN99811710A CN1125049C (zh) | 1998-10-02 | 1999-10-01 | 托拉沙得新晶体变型n |
CA002345789A CA2345789A1 (en) | 1998-10-02 | 1999-10-01 | New crystal modification iii of torasemide |
RU2001111831/04A RU2210569C2 (ru) | 1998-10-02 | 1999-10-01 | Кристаллическая модификация n-тораземида, способ ее получения, фармацевтическая форма |
HU0104009A HUP0104009A3 (en) | 1998-10-02 | 1999-10-01 | New crystal modification of torasemide, process for its preparation, its use as a ran material and pharmaceutical compositions containing it |
CZ20011031A CZ20011031A3 (cs) | 1998-10-02 | 1999-10-01 | Nová krystalová modifikace torasemidu |
AU62240/99A AU759291B2 (en) | 1998-10-02 | 1999-10-01 | New crystal modification N of torasemide |
BR9915018-2A BR9915018A (pt) | 1998-10-02 | 1999-10-01 | Modificação de cristal da torasemida |
IDW20010958A ID29931A (id) | 1998-10-02 | 1999-10-01 | Modifikasi kristal torasemida |
PL99346975A PL346975A1 (en) | 1998-10-02 | 1999-10-01 | New crystal modification iii of torasemide |
IL14215099A IL142150A0 (en) | 1998-10-02 | 1999-10-01 | New crystal modification iii of torasemide |
EEP200100194A EE04341B1 (et) | 1998-10-02 | 1999-10-01 | Torasemiidi kristallmodifikatsioon N, selle valmistamismeetod, kasutamine ja ravimvorm |
AT99949272T ATE286024T1 (de) | 1998-10-02 | 1999-10-01 | Neue kristallmodifikation n von torasemid |
PCT/HR1999/000023 WO2000020395A1 (en) | 1998-10-02 | 1999-10-01 | New crystal modification iii of torasemide |
SK423-2001A SK4232001A3 (en) | 1998-10-02 | 1999-10-01 | New crystal modification iii of torasemide |
JP2000574512A JP2002526532A (ja) | 1998-10-02 | 1999-10-01 | トラセミドの新規な結晶変態n型 |
NZ510898A NZ510898A (en) | 1998-10-02 | 1999-10-01 | Crystal modification N of torasemide |
DE69922977T DE69922977C5 (de) | 1998-10-02 | 1999-10-01 | Neue Kristallmodifikation von Torasemid |
TR2001/00909T TR200100909T2 (tr) | 1998-10-02 | 1999-10-01 | Torasemid'in yeni kristal modifikasyonu. |
YU24001A YU24001A (sh) | 1998-10-02 | 1999-10-01 | Nova kristalna modifikacija torasemida |
SI9930744T SI1117643T1 (en) | 1998-10-02 | 1999-10-01 | New crystal modification n of torasemide |
UA2001031966A UA72895C2 (uk) | 1998-10-02 | 1999-10-01 | Нова кристалічна модифікація n торасеміду |
PT99949272T PT1117643E (pt) | 1998-10-02 | 1999-10-01 | Nova modificacao n cristalina de torasemida |
ZA200102451A ZA200102451B (en) | 1998-10-02 | 1999-10-01 | New crystal modification III of torasemide. |
DK99949272T DK1117643T3 (da) | 1998-10-02 | 1999-10-01 | Ny krystalmodifikation N af torasemid |
EP99949272A EP1117643B1 (en) | 1998-10-02 | 1999-10-01 | New crystal modification n of torasemide |
DE29924789U DE29924789U1 (de) | 1998-10-02 | 1999-10-01 | Neue Kristallmodifikation N von Torasemid |
KR10-2001-7004079A KR100437307B1 (ko) | 1998-10-02 | 1999-10-01 | 토라세미드의 새로운 결정 변형태 ⅲ |
US09/434,439 US6399637B1 (en) | 1998-02-10 | 1999-11-05 | Crystal modification of torasemide |
NO20011633A NO317107B1 (no) | 1998-10-02 | 2001-03-30 | Ny krystallmodifikasjon av torasemid, fremgangsmate for fremstilling derav, samt farmasoytisk preparat |
BG105485A BG105485A (en) | 1998-10-02 | 2001-05-02 | New crystal modification n of torasemide |
US10/096,277 US6833379B2 (en) | 1998-10-02 | 2002-03-13 | Crystal modification of torasemide |
HK02102011.9A HK1040250B (zh) | 1998-10-02 | 2002-03-15 | 托拉沙得新晶體變型n |
US10/871,667 US20040229919A1 (en) | 1998-10-02 | 2004-06-21 | Crystal modification of torasemide |
US11/357,109 US20060205951A1 (en) | 1998-10-02 | 2006-02-21 | New crystal modification of torasemide |
US11/822,274 US20070276015A1 (en) | 1998-10-02 | 2007-07-03 | Crystal modification of torasemide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HR980532A HRP980532B1 (en) | 1998-10-02 | 1998-10-02 | Novel crystalline torasemide modification |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP980532A2 HRP980532A2 (en) | 2000-12-31 |
HRP980532B1 true HRP980532B1 (en) | 2005-06-30 |
Family
ID=10946825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR980532A HRP980532B1 (en) | 1998-02-10 | 1998-10-02 | Novel crystalline torasemide modification |
Country Status (32)
Country | Link |
---|---|
US (5) | US6399637B1 (da) |
EP (1) | EP1117643B1 (da) |
JP (1) | JP2002526532A (da) |
KR (1) | KR100437307B1 (da) |
CN (1) | CN1125049C (da) |
AT (1) | ATE286024T1 (da) |
AU (1) | AU759291B2 (da) |
BG (1) | BG105485A (da) |
BR (1) | BR9915018A (da) |
CA (1) | CA2345789A1 (da) |
CZ (1) | CZ20011031A3 (da) |
DE (2) | DE29924789U1 (da) |
DK (1) | DK1117643T3 (da) |
EE (1) | EE04341B1 (da) |
ES (1) | ES2237158T3 (da) |
HK (1) | HK1040250B (da) |
HR (1) | HRP980532B1 (da) |
HU (1) | HUP0104009A3 (da) |
ID (1) | ID29931A (da) |
IL (1) | IL142150A0 (da) |
NO (1) | NO317107B1 (da) |
NZ (1) | NZ510898A (da) |
PL (1) | PL346975A1 (da) |
PT (1) | PT1117643E (da) |
RU (1) | RU2210569C2 (da) |
SI (1) | SI1117643T1 (da) |
SK (1) | SK4232001A3 (da) |
TR (1) | TR200100909T2 (da) |
UA (1) | UA72895C2 (da) |
WO (1) | WO2000020395A1 (da) |
YU (1) | YU24001A (da) |
ZA (1) | ZA200102451B (da) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6394707B1 (en) | 1997-05-08 | 2002-05-28 | Jack Kennedy Metal Products & Buildings, Inc. | Yieldable mine roof support |
HRP980532B1 (en) | 1998-10-02 | 2005-06-30 | Pliva | Novel crystalline torasemide modification |
CZ2002404A3 (cs) * | 1999-08-11 | 2002-06-12 | Teva Pharmaceutical Industries Ltd. | Polymorfní formy torsemidu |
DE10013289A1 (de) * | 2000-03-17 | 2001-09-20 | Knoll Ag | Torasemid enthaltende pharmazeutische Zubereitungen |
HRP20000162B1 (en) | 2000-03-20 | 2004-06-30 | Pliva D D | Amorphous torasemide modification |
HRP20000328A2 (en) * | 2000-05-19 | 2002-02-28 | Pliva Farmaceutska Ind Dionik | Novel polymorph v of torasemide |
IN192178B (da) * | 2001-08-03 | 2004-03-06 | Ranbaxy Lab | |
HRP20020603B1 (en) * | 2002-07-19 | 2008-11-30 | Pliva D.D. | New process for the preparation of modification i n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridinesulfonamide |
CA2424644A1 (en) * | 2003-04-07 | 2004-10-07 | David John Mckenzie | Preparation of torasemide |
US20050065183A1 (en) * | 2003-07-31 | 2005-03-24 | Indranil Nandi | Fexofenadine composition and process for preparing |
DE602005025755D1 (de) * | 2004-06-04 | 2011-02-17 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
JP4406845B2 (ja) * | 2007-02-20 | 2010-02-03 | トヨタ自動車株式会社 | 二次電池電極材の剥離剤及び該剥離剤を用いた二次電池の処理方法 |
EP2705843A1 (en) * | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis |
CN104370805B (zh) * | 2013-08-13 | 2016-09-07 | 天津汉瑞药业有限公司 | 托拉塞米化合物 |
CN106038500A (zh) * | 2016-05-26 | 2016-10-26 | 南京正科医药股份有限公司 | 一种托拉塞米片 |
CN115417810B (zh) * | 2022-09-22 | 2023-10-10 | 南京正科医药股份有限公司 | 一种托拉塞米晶型ⅰ的精制方法 |
CN117486789A (zh) * | 2023-12-29 | 2024-02-02 | 江西中医药大学 | 一种托拉塞米共晶盐及其制备方法和应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1477664A (en) * | 1974-04-17 | 1977-06-22 | Christiaens Sa A | Pyridine derivatives |
US4055650A (en) * | 1974-04-17 | 1977-10-25 | A. Christiaens Societe Anonyme | Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines |
US4473693A (en) | 1978-08-04 | 1984-09-25 | Stewart Walter W | Aminonaphthalimide dyes for intracellular labelling |
DE3529529A1 (de) * | 1985-08-17 | 1987-02-19 | Boehringer Mannheim Gmbh | Verfahren zur herstellung einer stabilen modifikation von torasemid |
US6166041A (en) * | 1995-10-11 | 2000-12-26 | Euro-Celtique, S.A. | 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma |
HRP980532B1 (en) | 1998-10-02 | 2005-06-30 | Pliva | Novel crystalline torasemide modification |
US5914336A (en) * | 1998-06-02 | 1999-06-22 | Boehringer Mannheim Gmbh | Method of controlling the serum solubility of orally administered torasemide and composition relating thereto |
US6166045A (en) * | 1998-06-02 | 2000-12-26 | Roche Diagnostics Gmbh | Torasemide of modification III |
-
1998
- 1998-10-02 HR HR980532A patent/HRP980532B1/xx not_active IP Right Cessation
-
1999
- 1999-10-01 CN CN99811710A patent/CN1125049C/zh not_active Expired - Fee Related
- 1999-10-01 TR TR2001/00909T patent/TR200100909T2/xx unknown
- 1999-10-01 DK DK99949272T patent/DK1117643T3/da active
- 1999-10-01 WO PCT/HR1999/000023 patent/WO2000020395A1/en active IP Right Grant
- 1999-10-01 ES ES99949272T patent/ES2237158T3/es not_active Expired - Lifetime
- 1999-10-01 ZA ZA200102451A patent/ZA200102451B/en unknown
- 1999-10-01 UA UA2001031966A patent/UA72895C2/uk unknown
- 1999-10-01 DE DE29924789U patent/DE29924789U1/de not_active Expired - Lifetime
- 1999-10-01 EE EEP200100194A patent/EE04341B1/xx not_active IP Right Cessation
- 1999-10-01 CZ CZ20011031A patent/CZ20011031A3/cs unknown
- 1999-10-01 YU YU24001A patent/YU24001A/sh unknown
- 1999-10-01 IL IL14215099A patent/IL142150A0/xx unknown
- 1999-10-01 HU HU0104009A patent/HUP0104009A3/hu unknown
- 1999-10-01 NZ NZ510898A patent/NZ510898A/xx unknown
- 1999-10-01 RU RU2001111831/04A patent/RU2210569C2/ru not_active IP Right Cessation
- 1999-10-01 PL PL99346975A patent/PL346975A1/xx not_active Application Discontinuation
- 1999-10-01 JP JP2000574512A patent/JP2002526532A/ja active Pending
- 1999-10-01 DE DE69922977T patent/DE69922977C5/de not_active Revoked
- 1999-10-01 SK SK423-2001A patent/SK4232001A3/sk not_active Application Discontinuation
- 1999-10-01 EP EP99949272A patent/EP1117643B1/en not_active Revoked
- 1999-10-01 CA CA002345789A patent/CA2345789A1/en not_active Abandoned
- 1999-10-01 BR BR9915018-2A patent/BR9915018A/pt not_active IP Right Cessation
- 1999-10-01 AU AU62240/99A patent/AU759291B2/en not_active Ceased
- 1999-10-01 AT AT99949272T patent/ATE286024T1/de not_active IP Right Cessation
- 1999-10-01 SI SI9930744T patent/SI1117643T1/xx unknown
- 1999-10-01 ID IDW20010958A patent/ID29931A/id unknown
- 1999-10-01 KR KR10-2001-7004079A patent/KR100437307B1/ko not_active IP Right Cessation
- 1999-10-01 PT PT99949272T patent/PT1117643E/pt unknown
- 1999-11-05 US US09/434,439 patent/US6399637B1/en not_active Expired - Fee Related
-
2001
- 2001-03-30 NO NO20011633A patent/NO317107B1/no unknown
- 2001-05-02 BG BG105485A patent/BG105485A/xx unknown
-
2002
- 2002-03-13 US US10/096,277 patent/US6833379B2/en not_active Expired - Fee Related
- 2002-03-15 HK HK02102011.9A patent/HK1040250B/zh not_active IP Right Cessation
-
2004
- 2004-06-21 US US10/871,667 patent/US20040229919A1/en not_active Abandoned
-
2006
- 2006-02-21 US US11/357,109 patent/US20060205951A1/en not_active Abandoned
-
2007
- 2007-07-03 US US11/822,274 patent/US20070276015A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP980532B1 (en) | Novel crystalline torasemide modification | |
CA2360557A1 (en) | Biodegradable and thermosensitive polyphosphazenes and their preparation method | |
HRP20000092C1 (en) | Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof | |
AU2732395A (en) | A cathode material for lithium secondary batteries and a process and a precursor material for the production thereof | |
BR9909567B1 (pt) | composição agricolamente ativa, processo para a preparação de um composto, processos eletroquìmicos para a preparação de um composto e de hidróxido de n,n-dimetilpiperidìnio, composto, concentrado de suspensão, e, processo para regular o crescimento de planta. | |
CA2248953A1 (en) | Novel benzofuranone derivatives and process for producing the same | |
CA2171435A1 (en) | Effervescent granulated material and method for its preparation | |
WO1997013774A3 (fr) | Nouveaux derives de la 5-o-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs | |
IE800208L (en) | Production of isosorbide-5-nitrate | |
GR890300183T1 (en) | Method for preparing high purity cristalline lactulose and the product obtained | |
WO1996016557A3 (en) | Preparation of ice crystals suspension in sugar solution and its use for making confections | |
CA2089193A1 (en) | Diacetyl production | |
EP1195356A4 (en) | SHEET METAL TITANATE COMPOSITE AND METHOD FOR THE PRODUCTION THEREOF | |
IE780504L (en) | Preparing 5-(4-hydroxyphenyl) hydantoin | |
EP0922704A4 (en) | METHOD FOR THE PRODUCTION AND INTERMEDIATE OF 2- (10,11-DIHYDRO-10-OXODIBENZO [B, F] THIEPIN-2-YL) -PROPIONIC ACID | |
CA2297112A1 (en) | Dicyclanil polymorphs and hydrates and their preparation | |
CA2252952A1 (en) | Substituted aminomethylphenylsulphonylureas, their preparation, and their use as herbicides and plant growth regulators | |
Zachwieja | Single Crystal Growth and Structure Refinement of NaAu sub 2--a New Synthesis Method for Alkali Metal--Gold Compounds | |
JPS5711819A (en) | Preparation of crystalline zeolite | |
Cotterill et al. | The stereochemistry and reactions of some 3, 4-disubstituted chromans | |
Maurer et al. | Process for producing hydroxylapatite | |
Duboff et al. | Diacetyl production | |
EP0400558A3 (en) | Phenylacetic acid derivative | |
Xue et al. | Crystal structure of EuAu sub 2 Al sub 2 | |
Stepien-Damm et al. | Crystal structure of TbCoSi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
B1PR | Patent granted | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20080908 Year of fee payment: 11 |
|
PBON | Lapse due to non-payment of renewal fee |
Effective date: 20091003 |